A radically new therapeutic approach that aims to improve the quality of life of cancer patients and beyond: PROSION Therapeutics is a biotech & drug development company with a proprietary “LEGO-like” platform, aiming to address highly unmet medical needs by unlocking undruggable protein targets.

Starting off in oncology, our mission is to develop new drugs against hard-to-treat diseases. As of 2023, PROSION is backed by the European Commission and European deeptech investor Freigeist Capital.

Proline-rich motifs (PRM) control the function of biological complexes associated with disease progression. As their bio-active form adopts a unique helical shape, their binding domains are considered “undruggable”.

PROSION successfully established synthetic molecules called ProMs, as the first and currently only biomimetics of this helix pattern. As such, ProMs combine small molecule PK advantages with protein selectivity of biologics, thus unlocking the highly relevant yet undruggable PRM-targets.